Icure Pharmaceutical Incorporation Statistics

Total Valuation

Icure Pharmaceutical Incorporation has a market cap or net worth of KRW 72.98 billion. The enterprise value is 91.54 billion.

Market Cap	72.98B
Enterprise Value	91.54B

Important Dates

The next estimated earnings date is Friday, March 21, 2025.

Earnings Date	Mar 21, 2025
Ex-Dividend Date	n/a

Share Statistics

Icure Pharmaceutical Incorporation has 37.37 million shares outstanding. The number of shares has increased by 9.19% in one year.

Current Share Class	n/a
Shares Outstanding	37.37M
Shares Change (YoY)	+9.19%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	15.21%
Owned by Institutions (%)	0.41%
Float	31.69M

Valuation Ratios

The trailing PE ratio is 140.70.

PE Ratio	140.70
Forward PE	n/a
PS Ratio	1.21
PB Ratio	0.97
P/TBV Ratio	1.04
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	175.59
EV / Sales	1.51
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-4.98

Financial Position

The company has a current ratio of 0.90, with a Debt / Equity ratio of 0.48.

Current Ratio	0.90
Quick Ratio	0.57
Debt / Equity	0.48
Debt / EBITDA	n/a
Debt / FCF	-2.05
Interest Coverage	-4.67

Financial Efficiency

Return on equity (ROE) is -0.41% and return on invested capital (ROIC) is -12.44%.

Return on Equity (ROE)	-0.41%
Return on Assets (ROA)	-10.37%
Return on Capital (ROIC)	-12.44%
Revenue Per Employee	278.03M
Profits Per Employee	2.39M
Employee Count	218
Asset Turnover	0.38
Inventory Turnover	4.04

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -8.74% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-8.74%
50-Day Moving Average	2,073.32
200-Day Moving Average	2,161.37
Relative Strength Index (RSI)	48.37
Average Volume (20 Days)	507,899

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Icure Pharmaceutical Incorporation had revenue of KRW 60.61 billion and earned 521.32 million in profits. Earnings per share was 13.88.

Revenue	60.61B
Gross Profit	4.45B
Operating Income	-26.64B
Pretax Income	-565.71M
Net Income	521.32M
EBITDA	-17.87B
EBIT	-26.64B
Earnings Per Share (EPS)	13.88

Full Income Statement

Balance Sheet

The company has 22.49 billion in cash and 37.73 billion in debt, giving a net cash position of -15.24 billion or -407.70 per share.

Cash & Cash Equivalents	22.49B
Total Debt	37.73B
Net Cash	-15.24B
Net Cash Per Share	-407.70
Equity (Book Value)	78.37B
Book Value Per Share	2,008.40
Working Capital	-5.52B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -17.54 billion and capital expenditures -829.33 million, giving a free cash flow of -18.37 billion.

Operating Cash Flow	-17.54B
Capital Expenditures	-829.33M
Free Cash Flow	-18.37B
FCF Per Share	-491.45

Full Cash Flow Statement

Margins

Gross margin is 7.34%, with operating and profit margins of -43.95% and 0.86%.

Gross Margin	7.34%
Operating Margin	-43.95%
Pretax Margin	-0.93%
Profit Margin	0.86%
EBITDA Margin	-29.48%
EBIT Margin	-43.95%
FCF Margin	n/a

Dividends & Yields

Icure Pharmaceutical Incorporation does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-9.19%
Shareholder Yield	-9.19%
Earnings Yield	0.71%
FCF Yield	-25.16%

Stock Splits

The last stock split was on December 14, 2022. It was a forward split with a ratio of 1.2.

Last Split Date	Dec 14, 2022
Split Type	Forward
Split Ratio	1.2

Scores

Icure Pharmaceutical Incorporation has an Altman Z-Score of -0.2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.2
Piotroski F-Score	n/a